Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Global Market Report 2025

The poly(ADP-ribose) polymerase (PARP) inhibitors market size is expected to see rapid growth in the next few years. It will grow to $11.05 billion in 2029 at a compound annual growth rate (CAGR) of 14.6%. This projected growth is fueled by the rising incidence of cancer, broader adoption of precision-based treatments, an expanding elderly population, heightened public awareness regarding genetic testing, and an uptick in clinical research activity. Key trends anticipated during this period include progress in genomic sequencing, the emergence of companion diagnostics, the integration of advanced technologies in drug discovery, and the innovation of next-generation PARP inhibitors.

The increasing number of breast cancer cases is expected to drive the growth of the poly(ADP-ribose) polymerase (PARP) inhibitors market in the coming years. Breast cancer is a condition in which abnormal cells in the breast multiply uncontrollably, potentially leading to tumor formation and metastasis. This rise in breast cancer cases can be attributed to lifestyle-related factors such as obesity, lack of physical activity, and alcohol consumption, all of which elevate estrogen levels and contribute to tumor development. PARP inhibitors are used in breast cancer treatment by specifically targeting cancer cells with DNA repair deficiencies, especially those with BRCA mutations. These inhibitors help to suppress tumor growth by blocking DNA repair mechanisms, offering a more targeted treatment approach that improves patient outcomes while sparing healthy cells. For example, in March 2025, Breastcancer.org, a U.S.-based nonprofit organization, reported that breast cancer represents approximately 32% of all new cancer diagnoses, with an estimated 316,950 women projected to be diagnosed with invasive breast cancer and an additional 59,080 with non-invasive forms by 2025. As a result, the rising incidence of breast cancer is contributing to the expanding market for PARP inhibitors.

Leading companies in the PARP inhibitors market are increasingly investing in the development of innovative treatment strategies, such as combination therapies, to boost drug efficacy, minimize side effects, and extend the application of these therapies beyond oncology. Combination therapies involve the simultaneous use of multiple therapeutic agents - such as drugs, biologics, or radiation - to enhance overall treatment effectiveness and improve patient outcomes. For example, in June 2023, Merck & Co. Inc., a U.S.-based pharmaceutical company, and AstraZeneca plc, a UK-based pharmaceutical company, received FDA approval for olaparib (Lynparza) in combination with abiraterone and prednisone (or prednisolone) for the treatment of adults with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). Olaparib inhibits PARP enzymes, preventing the repair of damaged DNA in BRCA-mutated cancer cells and causing cell death. When combined with abiraterone and prednisone (or prednisolone), the therapy further enhances anti-cancer effects by reducing androgen production, which is essential for prostate cancer cell growth, thus slowing disease progression.

In July 2023, Ariceum Therapeutics GmbH, a biotechnology company based in Germany, acquired Theragnostics Ltd. for an undisclosed amount. This acquisition was aimed at expanding Ariceum’s radiopharmaceutical pipeline by incorporating next-generation PARP inhibitor therapies. Theragnostics Ltd., a UK-based biotechnology company, focuses on the development of radio-labeled PARP inhibitors for both cancer imaging and therapeutic applications.

Major players in the poly(adp-ribose) polymerase (PARP) inhibitors market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca Plc, GSK plc, Teva Pharmaceutical Industries Ltd., Eisai Co. Ltd., Genentech Inc., Ono Pharmaceutical Co. Ltd., Jiangsu Hengrui Medicine Co. Ltd., BeiGene, EMD Serono, Myriad Genetics, Clovis Oncology Inc., Repare Therapeutics Inc., Karyopharm Therapeutics, and Checkpoint Therapeutics Inc.

North America was the largest region in the poly(ADP-ribose) polymerase (PARP) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in poly(ADP-ribose) polymerase (PARP) inhibitors report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the poly(ADP-ribose) polymerase (PARP) inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The poly(ADP-ribose) polymerase (PARP) inhibitors market consists of sales of rubraca, talzenna, and pamiparib. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Poly(ADP-ribose) polymerase (PARP) inhibitors are a class of targeted cancer therapies designed to block the activity of PARP enzymes, which play a critical role in repairing DNA damage within cells. These inhibitors are particularly effective in targeting cancer cells with mutations in the BRCA1 or BRCA2 genes by disrupting their DNA repair mechanism, ultimately causing cell death.

The major types of PARP inhibitor drugs include niraparib, olaparib, rucaparib, talazoparib, veliparib, and others. Niraparib is specifically approved as a maintenance therapy for recurrent cancers of the ovary, fallopian tubes, and primary peritoneum. These medications are made available through multiple distribution channels such as hospital pharmacies, retail pharmacies, and online platforms. Their primary applications span various types of cancer, including ovarian, fallopian tube, breast, prostate, pancreatic, and more, with end-users comprising hospitals, clinics, research institutions, and others.

The poly(ADP-ribose) polymerase (PARP) inhibitors market size has grown rapidly in recent years. It will grow from $5.58 billion in 2024 to $6.41 billion in 2025 at a compound annual growth rate (CAGR) of 14.9%. The expansion during the historic period was driven by a rise in healthcare spending, an increasing preference for maintenance therapy, enhanced use in combination treatment protocols, a shift toward personalized medicine, and greater investments in oncology research pipelines.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.